The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,761.00
Bid: 1,757.50
Ask: 1,758.00
Change: 27.50 (1.59%)
Spread: 0.50 (0.028%)
Open: 1,736.00
High: 1,767.00
Low: 1,736.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: GlaxoSmithKline's Covid treatment copes with Omicron

Thu, 02nd Dec 2021 08:15

(Alliance News) - Markets continued to be whip-sawed by news about the Omicron variant of Covid-19, but there was some good news from GlaxoSmithKline early Thursday.

GSK said that preclinical data showed sotrovimab, an investigational monoclonal antibody treatment for Covid-19, retains activity against key mutations of the new variant.

The findings were generated through pseudo-virus testing of specific individual mutations found in Omicron. GSK, alongside collaboration partner Vir Biotechnology, are now completing in vitro pseudo-virus testing to confirm the results. An update is expected by the end of 2021.

"Though early, these pre-clinical data support our long-held view on the potential for sotrovimab to maintain its activity as the virus continues to mutate," said Hal Barron, chief scientific officer & president for R&D at GSK.

Separately, the UK Medicines & Healthcare products Regulatory Agency on Thursday said it has authorised sotrovimab to treat people at high risk of developing severe Covid-19.

"It is too early to know whether the omicron variant has any impact on sotrovimab's effectiveness, but the MHRA will work with the company to establish this," the regulator said.

Glaxo shares were up 0.3% amid an overall down market.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: down 1.0% at 7,098.63

----------

Hang Seng: up 0.5% at 23,765.78

Nikkei 225: closed down 0.7% at 27,753.37

S&P/ASX 200: closed down 0.2% at 7,225.20

----------

DJIA: closed down 461.68 points, or 1.3%, at 34,022.04.

S&P 500: closed down 53.96 points, or 1.2%, at 4,513.04

Nasdaq Composite: closed down 283.64 points, or 1.8%, at 15,254.05

----------

EUR: down at USD1.1314 (USD1.1325)

GBP: down at USD1.3283 (USD1.3315)

USD: up at JPY113.29 (JPY113.02)

Gold: down at USD1,775.13 per ounce (USD1,785.55)

Oil (Brent): down at USD69.88 a barrel (USD71.88)

(changes since previous London equities close)

----------

ECONOMICS AND GENERAL

----------

Thursday's key economic events still to come

OPEC and non-OPEC ministerial meeting

1100 CET EU unemployment

1100 CET EU producer price index

0830 EST US initial jobless claims

1030 EST US EIA weekly natural gas storage report

----------

Major oil producers are due to meet Thursday to decide on output levels from January onwards, which could be frozen as the new Covid variant Omicron sparks turmoil. The OPEC+ alliance led by Saudi Arabia and Russia has so far resisted US-led pressure to significantly boost output to rein in surging energy prices, AFP reports. The emergence of the new variant has further complicated the equation, leading to countries reinstating travel bans and mulling further restrictions that could tighten demand and hurt oil prices. The 13 members of the Organization of the Petroleum Exporting Countries and their 10 allies are due to meet from 1300 GMT via video conference after technical discussions. Analysts predict the alliance will decide to stop modestly increasing output by 400,000 barrels per day every month as they had planned and as they have been doing since May.

----------

BROKER RATING CHANGES

----------

RBC RAISES SUPERDRY TO 'OUTPERFORM' (SECTOR PERFORM) - PRICE TARGET 425 (390) PENCE

----------

COMPANIES - FTSE 100

----------

Dechra Pharmaceuticals and Electrocomponents will join the FTSE 100 index on December 20 at the expense of Darktrace and Johnson Matthey, FTSE Russell announced late Wednesday.

----------

COMPANIES - FTSE 250

----------

In the FTSE 250, Petershill Partners and Provident Financial will replace AO World and Restaurant Group on December 20.

----------

Outsourcer Serco reiterated 2021 guidance and laid out new medium-term targets. Ahead of a capital markets day being held on Thursday, Serco said it expects its addressable market to grow around 2% to 3% per year over the medium-term, and it expects its own revenue will grow at twice this rate, at around 4% to 6% from a base year of 2022. It is targeting margin growth of 50 to 100 basis points to 5% to 6%, as well as the conversation of at least 80% of operating profit into cash. Serco plans to reduce dividend cover to around 3 times from 4 times. Chief Executive Rupert Soames said reduced government spending on the pandemic will knock revenue and profit in 2022, but he anticipates good growth in the parts of the business not involved in Covid services.

----------

AJ Bell rewarded shareholders with a special dividend after reporting a record year. The retail investment platform also said it has appointed Peter Birch as chief financial officer. He joins from accountants Deloitte, where he is currently a financial services audit and assurance partner. AJ Bell's total customers rose 30% to 382,754 and assets under administration grew to stand at GBP72.8 billion on September 30, up 29% from a year ago. Revenue in the financial year increased 15% to GBP145.8 million and pretax profit expanded 13% to GBP55.1 million. AJ Bell raised its final dividend by 13% to 4.50p and, in light of the strong results, also declared a special payout of 5.00p. This took the year's total dividend to 11.96p, nearly double the 6.16p paid out for the year before. Chief Executive Andy Bell said the special dividend reflects the company's confidence in its outlook. Looking ahead, AJ Bell said it expects customer activity to remain at normalised levels following elevated activity during lockdown. However, it noted that any increase in interest rates is likely to have a favourable impact on recurring ad valorem revenue.

----------

Luxury car maker Aston Martin said Kenneth Gregor is stepping down as chief financial officer for personal reasons, departing no later than June 30. Aston Martin has started looking for his successor.

----------

COMPANIES - MAIN MARKET AND AIM

----------

Lord Rothermere's acquisition vehicle raised its takeover offer for Daily Mail & General Trust by 5.9% to 270 pence per share in cash from 255p previously. Rothermere Continuation also lowered its acceptance condition to 50% of DMGT, including its own shares. It said it currently owns or has acceptance for its offer for 41.8% of DMGT shares. The independent directors of DMGT unanimously recommended the new offer to shareholders. In addition to the 270p per shares, all shareholders will receive a special distribution of 568 pence and 0.5749 of a Cazoo share per DMGT share.

----------

Ryanair's November traffic jumped to 10.2 million after carrying just 2.0 million passengers a year ago. However, the figure was the lowest since July, when traffic was 9.3 million, having carried in excess of 11 million passengers in October. The Irish low-cost airline operated over 62,300 flights in November with an 86% load factor, improved from 62% a year prior.

----------

COMPANIES - GLOBAL

----------

Tesla says it has officially moved its corporate headquarters from Silicon Valley to a large factory under construction near Austin, Texas. The electric car company made the announcement late on Wednesday in a filing with US securities regulators. Chief Executive Elon Musk had said at the company's annual meeting in October that the move was coming. The filing said the relocation from Palo Alto, California, to what Tesla calls a "gigafactory" near Austin was done on Wednesday. In US regulatory filings at the end of last year, Tesla said it had about 71,000 employees worldwide. Company news releases in 2020 said about 10,000 worked at the Palo Alto headquarters and 10,000 at its factory in Fremont, California.

----------

Thursday's shareholder meetings

Apollon Formularies PLC - AGM

CQS New City Yield Fund Ltd - AGM

DCD Media PLC - GM re sale of business to 108 Media

essensys PLC - AGM

Ferguson PLC - AGM

Limitless Earth PLC - AGM

VinaCapital Vietnam Opportunity Fund Ltd - AGM

Starcrest Education Ltd - EGM re acquisition of National Training Co

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
2 May 2024 19:57

GSK knew about Zantac cancer risk, attorneys tell jury in first trial

May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.

Read more
2 May 2024 09:48

LONDON BROKER RATINGS: Deutsche Bank likes TP ICAP but says sell CMC

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 May 2024 19:39

Bird flu testing shows more dairy products are safe, US FDA says

CHICAGO, May 1 (Reuters) - Preliminary results of tests on additional dairy products show that pasteurization inactivates the bird flu virus, the U.S. Food and Drug Administration said on Wednesday.

Read more
1 May 2024 17:31

UK's FTSE 100 slips ahead of Fed outcome, energy stocks weigh

FTSE 100 down 0.3%, FTSE 250 off 0.2%

*

Read more
1 May 2024 16:56

LONDON MARKET CLOSE: FTSE 100 down ahead of US interest rate decision

(Alliance News) - Stock prices in London closed mostly in the red on Wednesday, as investors eye the latest interest rate decision from the US Federal Reserve this evening.

Read more
1 May 2024 16:42

London close: Stocks fall ahead of US Fed decision

(Sharecast News) - London markets closed lower on Wednesday, as investors digested the latest UK manufacturing data and anticipated an impending policy announcement from the US Federal Reserve.

Read more
1 May 2024 11:55

LONDON MARKET MIDDAY: FTSE 100 treads water as Fed takes centre-stage

(Alliance News) - London's FTSE 100 traded off session highs heading into Wednesday afternoon, as some pre-Federal Reserve decision nerves kicked in.

Read more
1 May 2024 10:54

GSK raises profit outlook on strong vaccine, HIV drug sales

FY profit forecast raised to 8-10%

*

Read more
1 May 2024 08:57

LONDON MARKET OPEN: FTSE 100 shakes off New York slump before Fed

(Alliance News) - Stock prices in London opened mixed on Wednesday, with the FTSE 100 brushing off some pre-Federal Reserve decision trepidation to record an early rise, while the dollar climbed on the expectation that Jerome Powell will sound hawkish in his press conference later.

Read more
1 May 2024 08:50

TOP NEWS: GSK expects momentum to continue after strong first quarter

(Alliance News) - GSK PLC on Wednesday raised its annual earnings forecast, and said it expects sales growth at the top-end of guidance, after a "strong" start to the year.

Read more
1 May 2024 07:46

LONDON BRIEFING: GSK ups outlook; Next first-quarter beats forecast

(Alliance News) - Equities in London are called to open flat on Wednesday, ahead of the latest Federal Reserve interest rate decision, while a host of financial markets in mainland Europe and beyond are closed for public holidays.

Read more
1 May 2024 07:36

GSK lifts annual guidance on strong virus treatment sales

(Sharecast News) - UK pharmaceutical giant GSK lifted annual profits guidance on Wednesday, as it pinned its hopes on demand for its respiratory virus and shingles treatments.

Read more
30 Apr 2024 23:46

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 22:39

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.